-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Benzinga·07/23/2026 14:21:13
語音播報
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.